Hemodynamic changes by recombinant erythropoietin therapy in hemodialyzed patients.
نویسندگان
چکیده
Recombinant human erythropoietin therapy was given to 15 patients undergoing long-term hemodialysis with normal cardiac function. None of the patients had hypertension before the erythropoietin therapy and had received no antihypertensive agents. Before and after the erythropoietin therapy M-mode and pulsed Doppler echocardiographic studies, measurements of plasma volume by radioiodinated human serum albumin, and measurements of atrial natriuretic factor were carried out. After 6 weeks of erythropoietin therapy, hematocrit increased from 20.0 to 33.0%. Cardiac output, stroke volume, left ventricular diastolic dimensions, and left ventricular wall stress were all significantly decreased. Total peripheral resistance, interventricular septal thickness, and left ventricular posterior wall thickness were significantly increased. In Doppler echocardiographic studies, the mean velocity of aortic ejection flow and left ventricular acceleration time were decreased. The blood volume derived from plasma volume and hematocrit was not changed, whereas plasma atrial natriuretic factor concentration was significantly decreased. These data suggest that recombinant human erythropoietin administration suppressed the hyperdynamic cardiac state that was required to maintain oxygen delivery to the peripheral tissues in severe uremic anemia.
منابع مشابه
Influence on recombinant human erythropoietin on hemorheological profiles of hemodialyzed patients.
متن کامل
Biochemical markers of iron status in hemodialysis patients.
INTRODUCTION Secondary lack of iron in patients on hemodyalisis is the main cause of inadequate answer on therapy of recombinant human erythropoietin (rHuEPO). Therefore, it is very important to follow the status of iron in these patients. OBJECTIVES The objectives of our study were to define the value of hemoglobin content in reticulocytes as predictor of functional iron deficiency on hemodi...
متن کاملبررسی وضعیت ذخایر آهن و شیوع کم خونی فقر آهن در مبتلایان به بیماری مزمن کلیوی در مراحل پیش از دیالیز (pre-dialysis) و همودیالیز نگهدارنده
Background and Objective: Anemia is one of the major disabling consequences in chronic kidney (CKD) disease which has different etiologies .Inadequate production of Erythropoietin (EPO) is the main cause of anemia. Iron shortage is the other important cause. The aim of this study is to evaluate Anemia Prevalence and iron storage in CKD patients in pre-dialysis and hemodialysis stages. Mater...
متن کاملPHARMA COKINETICS OF RECOMBINANT ERYTHROPOIETIN AND RED CELL METABOLISM IN HAEMODIALYSIS PATIENTS
The pharmacokinetics of recombinant human erythropoietin (rHuEpo) administered intravenously has been investigated in a group of five patients with chronic renal failure who were dialysis-dependent. The half-life of circulating erythropoietin decreased from 7.9±OA hr (mean ±SO) at the beginning of treatment to 6.2±O.6 hr after 6 weeks and 5A±O.9 hr after 4 months of treatment. In spite of t...
متن کاملHuman erythropoietin improves blood plasma phospholipids concentration in chronically hemodialyzed patients.
Human Erythropoietin Improves Blood Plasma Phospholipids Concentration in Chronically Hemodialyzed Patients W. Wojciech Krawczyk A. Andrzej Ledwożyw A. Anna Dmoszyńska K. Krzysztof Marczewski Department of Internal Medicine and Dialysis Unit, Regional Hospital, Chetm, Department of Pathophysiology, Agricultural Academy, Department of Hematology, Medical School, Institute of Agricultural Medicin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Hypertension
دوره 15 3 شماره
صفحات -
تاریخ انتشار 1990